



65 West Watkins Mill Road  
Gaithersburg, MD 20878  
tel: 240-632-0740  
fax: 240-632-0735  
[www.genvec.com](http://www.genvec.com)

**FOR IMMEDIATE RELEASE:**

**CONTACT:**

**Danielle M. DiPirro**  
**Corporate Communications Specialist**  
**(301) 944-1877**  
[ddipirro@genvec.com](mailto:ddipirro@genvec.com)

## **GENVEC ANNOUNCES FIRST QUARTER 2009 RESULTS CONFERENCE CALL**

**GAITHERSBURG, MD** – April 30, 2009 – GenVec, Inc. (Nasdaq: GNVC) announced that it will release financial results for the first quarter ended March 31, 2009 on Thursday, May 7, 2009 after market close. GenVec will hold a conference call at 10:00 a.m. EDT on Friday, May 8, 2009 to discuss the company's first quarter results.

To listen to the live conference call, please dial 888-679-8033 (U.S. or Canada) or 617-213-4846 (international) and use access code 77642733. Participants may pre-register for the call anytime at: <https://www.theconferencingservice.com/prereg/key.process?key=PAQTA3XK9>. Pre-registrants will be issued a PIN number to use when dialing into the live call, which will provide quick access to the conference. An audio replay of the conference call will be available starting at 12:00 p.m. on May 8, 2008 through May 15, 2008. To listen to the audio replay, dial 888-286-8010 (U.S. or Canada) or 617-801-6888 (international) and use access code 86844565.

A live webcast of the conference call will be available on the Company's website and will be archived for 30 days. To access the webcast or the replay, go to [www.genvec.com](http://www.genvec.com), click on "Investor Relations," and click on "Webcasts and Data."

### ***About GenVec***

GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade™, is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at [www.genvec.com](http://www.genvec.com) and in the company's various filings with the Securities and Exchange Commission.

###